290 related articles for article (PubMed ID: 12646342)
1. Efficacy of rosuvastatin 10 mg in patients with the metabolic syndrome.
Ballantyne CM; Stein EA; Paoletti R; Southworth H; Blasetto JW
Am J Cardiol; 2003 Mar; 91(5A):25C-27C; discussion 28C. PubMed ID: 12646342
[TBL] [Abstract][Full Text] [Related]
2. Comparison of effects on low-density lipoprotein cholesterol and high-density lipoprotein cholesterol with rosuvastatin versus atorvastatin in patients with type IIa or IIb hypercholesterolemia.
Davidson M; Ma P; Stein EA; Gotto AM; Raza A; Chitra R; Hutchinson H
Am J Cardiol; 2002 Feb; 89(3):268-75. PubMed ID: 11809427
[TBL] [Abstract][Full Text] [Related]
3. Guidelines for lowering lipids to reduce coronary artery disease risk: a comparison of rosuvastatin with atorvastatin, pravastatin, and simvastatin for achieving lipid-lowering goals.
Shepherd J; Hunninghake DB; Barter P; McKenney JM; Hutchinson HG
Am J Cardiol; 2003 Mar; 91(5A):11C-17C; discussion 17C-19C. PubMed ID: 12646338
[TBL] [Abstract][Full Text] [Related]
4. Lipid and apolipoprotein ratios: association with coronary artery disease and effects of rosuvastatin compared with atorvastatin, pravastatin, and simvastatin.
Rader DJ; Davidson MH; Caplan RJ; Pears JS
Am J Cardiol; 2003 Mar; 91(5A):20C-23C; discussion 23C-24C. PubMed ID: 12646340
[TBL] [Abstract][Full Text] [Related]
5. Comparative effects of simvastatin and atorvastatin in hypercholesterolemic patients with characteristics of metabolic syndrome.
Hunninghake DB; Ballantyne CM; Maccubbin DL; Shah AK; Gumbiner B; Mitchel YB
Clin Ther; 2003 Jun; 25(6):1670-86. PubMed ID: 12860491
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of rosuvastatin compared with other statins at selected starting doses in hypercholesterolemic patients and in special population groups.
Blasetto JW; Stein EA; Brown WV; Chitra R; Raza A
Am J Cardiol; 2003 Mar; 91(5A):3C-10C; discussion 10C. PubMed ID: 12646336
[TBL] [Abstract][Full Text] [Related]
7. Effects of rosuvastatin versus atorvastatin, simvastatin, and pravastatin on non-high-density lipoprotein cholesterol, apolipoproteins, and lipid ratios in patients with hypercholesterolemia: additional results from the STELLAR trial.
Jones PH; Hunninghake DB; Ferdinand KC; Stein EA; Gold A; Caplan RJ; Blasetto JW;
Clin Ther; 2004 Sep; 26(9):1388-99. PubMed ID: 15531001
[TBL] [Abstract][Full Text] [Related]
8. One-year efficacy and safety of rosuvastatin + fenofibric acid combination therapy in patients with mixed dyslipidemia: evaluation of dose response.
Ferdinand KC; Davidson MH; Kelly MT; Setze CM
Am J Cardiovasc Drugs; 2012 Apr; 12(2):117-25. PubMed ID: 22263674
[TBL] [Abstract][Full Text] [Related]
9. Alteration of relation of atherogenic lipoprotein cholesterol to apolipoprotein B by intensive statin therapy in patients with acute coronary syndrome (from the Limiting UNdertreatment of lipids in ACS With Rosuvastatin [LUNAR] Trial).
Ballantyne CM; Pitt B; Loscalzo J; Cain VA; Raichlen JS
Am J Cardiol; 2013 Feb; 111(4):506-9. PubMed ID: 23237107
[TBL] [Abstract][Full Text] [Related]
10. On-treatment non-high-density lipoprotein cholesterol, apolipoprotein B, triglycerides, and lipid ratios in relation to residual vascular risk after treatment with potent statin therapy: JUPITER (justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin).
Mora S; Glynn RJ; Boekholdt SM; Nordestgaard BG; Kastelein JJ; Ridker PM
J Am Coll Cardiol; 2012 Apr; 59(17):1521-8. PubMed ID: 22516441
[TBL] [Abstract][Full Text] [Related]
11. Comparison of rosuvastatin with atorvastatin, simvastatin and pravastatin in achieving cholesterol goals and improving plasma lipids in hypercholesterolaemic patients with or without the metabolic syndrome in the MERCURY I trial.
Stender S; Schuster H; Barter P; Watkins C; Kallend D;
Diabetes Obes Metab; 2005 Jul; 7(4):430-8. PubMed ID: 15955130
[TBL] [Abstract][Full Text] [Related]
12. Effects of rosuvastatin and atorvastatin on LDL and HDL particle concentrations in patients with metabolic syndrome: a randomized, double-blind, controlled study.
Rosenson RS; Otvos JD; Hsia J
Diabetes Care; 2009 Jun; 32(6):1087-91. PubMed ID: 19265025
[TBL] [Abstract][Full Text] [Related]
13. Comparative study of low doses of rosuvastatin and atorvastatin on lipid and glycemic control in patients with metabolic syndrome and hypercholesterolemia.
Park JS; Kim YJ; Choi JY; Kim YN; Hong TJ; Kim DS; Kim KY; Jeong MH; Chae JK; Oh SK; Seong IW
Korean J Intern Med; 2010 Mar; 25(1):27-35. PubMed ID: 20195400
[TBL] [Abstract][Full Text] [Related]
14. Comparative effects of rosuvastatin and atorvastatin across their dose ranges in patients with hypercholesterolemia and without active arterial disease.
Schneck DW; Knopp RH; Ballantyne CM; McPherson R; Chitra RR; Simonson SG
Am J Cardiol; 2003 Jan; 91(1):33-41. PubMed ID: 12505568
[TBL] [Abstract][Full Text] [Related]
15. Rosuvastatin alone or with extended-release niacin: a new therapeutic option for patients with combined hyperlipidemia.
Capuzzi DM; Morgan JM; Carey CM; Intenzo C; Tulenko T; Kearney D; Walker K; Cressman MD
Prev Cardiol; 2004; 7(4):176-81. PubMed ID: 15539964
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the efficacy of rosuvastatin versus atorvastatin, simvastatin, and pravastatin in achieving lipid goals: results from the STELLAR trial.
McKenney JM; Jones PH; Adamczyk MA; Cain VA; Bryzinski BS; Blasetto JW;
Curr Med Res Opin; 2003; 19(8):689-98. PubMed ID: 14687438
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of low-dose rosuvastatin in patients with type 2 diabetes and hypo high-density lipoprotein cholesterolaemia.
Katabami T; Murakami M; Kobayashi S; Matsui T; Ujihara M; Takagi S; Higa M; Ichijo T; Ohta A; Tanaka Y
J Int Med Res; 2014 Apr; 42(2):457-67. PubMed ID: 24595147
[TBL] [Abstract][Full Text] [Related]
18. Rosuvastatin 5 and 10 mg/d: a pilot study of the effects in hypercholesterolemic adults unable to tolerate other statins and reach LDL cholesterol goals with nonstatin lipid-lowering therapies.
Glueck CJ; Aregawi D; Agloria M; Khalil Q; Winiarska M; Munjal J; Gogineni S; Wang P
Clin Ther; 2006 Jun; 28(6):933-42. PubMed ID: 16860175
[TBL] [Abstract][Full Text] [Related]
19. Daily and intermittent rosuvastatin 5 mg therapy in statin intolerant patients: an observational study.
Meek C; Wierzbicki AS; Jewkes C; Twomey PJ; Crook MA; Jones A; Viljoen A
Curr Med Res Opin; 2012 Mar; 28(3):371-8. PubMed ID: 22256801
[TBL] [Abstract][Full Text] [Related]
20. Achieving LDL cholesterol, non-HDL cholesterol, and apolipoprotein B target levels in high-risk patients: Measuring Effective Reductions in Cholesterol Using Rosuvastatin therapY (MERCURY) II.
Ballantyne CM; Bertolami M; Hernandez Garcia HR; Nul D; Stein EA; Theroux P; Weiss R; Cain VA; Raichlen JS
Am Heart J; 2006 May; 151(5):975.e1-9. PubMed ID: 16644314
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
